Global Recombinant Trypsin Solution Revenue Is Nearly 37 Million USD In 2017
Thursday, 01 Nov, 2018
In the last several years, global market of recombinant trypsin solution developed smoothly, with an average growth rate of 6.66%. In 2017, global revenue of recombinant trypsin solution is nearly 37 million USD; the actual production is about 120 K L.

The classification of recombinant trypsin solution includes solid type, liquid type. And the proportion of liquid type in 2017 is about 65.53%.

Recombinant trypsin solution is widely used for insulin manufacturing, vaccines manufacturing and cell culture. The most proportion of recombinant trypsin solution is used for cell culture, and the proportion in 2017 is about 39%.

Europe region is the largest supplier of recombinant trypsin solution, with a production market share nearly 66% in 2017. North America is the second largest supplier of recombinant trypsin solution, enjoying production market share nearly 27% in 2017.

North American is the largest consumption place, with a consumption market share nearly 42% in 2017. Following North American, North American is the second largest consumption place with the consumption market share of 33%. 

Market competition is intense. Novozymes, Thermo Fisher, Roche, BBI?Group, Merck, etc. are the leaders of the industry, and they hold key patents, with high-end customers.